Wenhu Liu | Pharmacology | Excellence in Research

Published on by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in Research 

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

🎓 Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

💼 Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

🔬 Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

🏆 Awards 

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

📚Top Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

  • Journal: Phytomedicine

  • Year: 2025 (In press)

  • Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

  • Journal: European Journal of Pharmaceutics and Biopharmaceutics

  • Year: 2024

  • Volume: 203

  • Article Number: 114475

  • Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

  • Journal: Neurotoxicology

  • Year: 2023

  • Volume: 99

  • Pages: 162–176

  • Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

  • Journal: Clinical Proteomics

  • Year: 2022

  • Volume: 19

  • Article Number: 18

  • Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

  • Journal: Frontiers in Physiology

  • Year: 2022

  • Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

  • Journal: International Journal of Medical Sciences

  • Year: 2020

  • Volume: 17

  • Issue: 18

  • Pages: 3146–3164

  • Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

  • Journal: Chinese Journal of Analytical Chemistry

  • Year: 2020

  • Volume: 48

  • Issue: 2

  • Pages: 187–196

  • Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.

Tang Jin-Bao | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Tang Jin-Bao | Pharmacology | Best Researcher Award

Prof. Dr Tang Jin-Bao,Shandong Second Medical University,China

Prof. Dr. Jin-Bao Tang, a licensed pharmacist in China, is a professor at Shandong Second Medical University. He earned his Ph.D. in Microbial and Biochemical Pharmacy from Shandong University in 2023. An esteemed graduate sponsor in Shandong Province, he specializes in Biotechnological Pharmaceutics and Pharmaceutical Engineering. His research focuses on developing novel immunoassay biosensors for proteins and peptides. With multiple high-impact publications in Food Chemistry and Analytical Bioanalytical Chemistry, he has pioneered advanced immunosensor technologies. His innovative contributions to biosensor development enhance precision in food safety and biomedical analysis. 🔬📚

Publication Profile

Scopus

Education

Prof. Dr. Jin-Bao Tang 🎓 holds a Doctorate in Microbial and Biochemical Pharmacy from Shandong University (2023) and is a licensed pharmacist in China. As a distinguished professor at Shandong Second Medical University, he plays a vital role in educating future pharmaceutical professionals in Biotechnological Pharmaceutics and Pharmaceutics Engineering 🧪. His dedication to academia is evident through his mentorship and contributions to pharmaceutical sciences. Recognized as an excellent graduate sponsor of Shandong Province 🏆, Dr. Tang’s expertise and commitment continue to shape the next generation of researchers and industry leaders in the field of pharmacy. 💊

Scientific Community

Prof. Dr. Jin-Bao Tang 🧑‍🔬 has made a significant impact in the scientific community through his groundbreaking research in biotechnology and pharmacology. His publications appear in prestigious journals such as Food Chemistry, International Journal of Biological Macromolecules, Food Control, and Analytical Bioanalytical Chemistry 📚. His collaborative work has led to advancements in oriented antibody immobilization, photoconjugation strategies, and biosensor technology 🧪, with profound implications for public health, biotechnology, and pharmacological applications. Through his innovative contributions, Prof. Tang continues to shape the future of pharmaceutical sciences, enhancing diagnostic and therapeutic approaches for global healthcare. 🌍💊

Research Contributions

Prof. Dr. Tang Jin-Bao’s research revolves around developing novel immunoassay biosensors for protein and peptide detection 🧪🔬. His pioneering work has significantly advanced biosensing technology, particularly in food safety and biomedical analysis 🍎⚕️. Over the past five years, his high-impact publications have introduced innovative techniques such as electrochemical immunosensors for aflatoxin detection ⚡, bioluminescent immunoassays using antibody-nanoluciferase conjugates ✨, and Fc-specific antibody modifications for enhanced biosensor performance 🧫. Additionally, his photoconjugation strategies have led to stable fluorescent antibody fabrication 🌟. These breakthroughs contribute immensely to food safety, pharmaceutical analysis, and immunodiagnostics, demonstrating the real-world impact of his research. 🚀

Research Focus

Prof. Dr. Jin-Bao Tang’s research primarily focuses on biosensors 🧪, immunoassays 🏥, and antibody engineering 🧬 for food safety and biomedical applications. His work involves developing electrochemical immunosensors ⚡, bioluminescent assays 💡, and advanced antibody modifications 🏗️ to enhance the detection of harmful contaminants like aflatoxin B1 🍄⚠️. He explores oriented antibody immobilization 🎯 to improve sensitivity and specificity in bioanalytical methods. Additionally, his research extends to drug delivery systems 💊, particularly in pulsatile release formulations ⏳, using innovative polymers. His contributions advance food safety 🥗, biomedical diagnostics 🏥, and pharmaceutical technologies 💊 for global health and safety.

Publication Top Notes

A facile and effective electrochemical immunosensor based on controlled and oriented immobilization of natural antibodies for sensitive detection of aflatoxin B1

Development of a bioluminescent immunoassay based on Fc-specific conjugated antibody–nanoluciferase immunoreagents for determining aflatoxin B1

Fabrication of cysteine-modified antibodies with Fc-specific conjugation for covalent and oriented immobilization of native antibodies

Preparation of enteric capsules with pulsatile drug delivery potential using pullulan and polyacrylic acid resin III

Prof Dr. Ronit Sverdlov|Pharmacology|Best Researcher Award

Published on by Top Pharmaceutical

Prof Dr. Ronit Sverdlov|Pharmacology|Best Researcher Award

Prof Dr. Ronit Sverdlov at Maastricht University,Netherlands

PROFILE  

ORCID

Scopus

 

Early Academic Pursuits 🎓

Dr. Ronit Shiri-Sverdlov’s academic journey began with a Master’s degree in Biochemistry and Cellular Biology from Tel-Aviv University in Israel, where she graduated magna cum laude. This period was instrumental in shaping her deep interest in cellular and molecular mechanisms, a theme that would remain central to her later work. Building on her foundational knowledge, she pursued a Ph.D. in Molecular Genetics at Tel-Aviv University’s Sheba Medical Center, under the supervision of Prof. E. Friedman. Her doctoral research, focused on identifying germline mutations in the BRCA1 and BRCA2 genes among high-risk Jewish and Arab populations, underscored her commitment to precision genetics and earned her a magna cum laude distinction upon graduation in 2002.

Professional Endeavors 💼

Dr. Shiri-Sverdlov joined Maastricht University’s Department of Molecular Genetics in 2001 as a postdoctoral researcher, working with Prof. M.H. Hofker. Her early postdoctoral work provided the groundwork for her lifelong focus on metabolic health, hepatic inflammation, and cholesterol metabolism. In 2004, she transitioned into a faculty position, first as an Assistant Professor and later, an Associate Professor by 2012. In 2016, she was appointed a Full Professor of Hepatic Inflammation and Metabolic Health, reflecting her leadership and expertise in the field. Dr. Shiri-Sverdlov currently leads a vibrant research team within the Faculty of Health, Medicine, and Life Sciences at Maastricht University, where she oversees projects focusing on liver disease, metabolic health, and inflammation under the NUTRIM School of Nutrition and Translational Research in Metabolism.

Contributions and Research Focus 🔬

Dr. Shiri-Sverdlov’s research centers on understanding and combating liver-related diseases, particularly non-alcoholic steatohepatitis (NASH), through molecular insights into cholesterol trafficking and hepatic inflammation. Her investigations have brought critical attention to lysosomal dysfunction as a biomarker for early NASH detection. This research has garnered substantial support, including a €1 million TKI grant in 2017 and several large fellowships from the Dutch Digestive Foundation and NWO ZonMw. Her work emphasizes the role of cholesterol metabolism in Kupffer cells (liver macrophages) and its impact on inflammatory pathways—a field where her studies continue to yield promising therapeutic insights.

Accolades and Recognition 🏆

Over the years, Dr. Shiri-Sverdlov has earned numerous prestigious awards. Her early career was marked by the VENI, VIDI, and ASPASIA fellowships from NWO ZonMw, which collectively supported her pioneering work in cholesterol metabolism and liver inflammation. She received the Marie Sklodowska-Curie Seal of Excellence in 2018, reflecting her proposal’s high evaluation score. She was also awarded the Education Prize by Maastricht University in 2018 for her leadership in developing the Biomedical Sciences curriculum. Additionally, she has been nominated for multiple awards, reflecting her influence in both research and teaching.

Impact and Influence 🌐

Dr. Shiri-Sverdlov has made a significant impact in the field of hepatic health through her research and mentorship. Her work on hepatic lysosomal biomarkers has been pivotal in early disease detection for NASH, with implications for both clinical practice and drug development. As a member of key grant committees, including the Netherlands Organization for Scientific Research (NWO) and the Novo Nordisk Foundation, she actively shapes the research landscape. Her collaboration with researchers across Europe, including those at the University of Reading and Strasbourg University, has contributed to a robust network of shared knowledge and advances in metabolic health.

Legacy and Future Contributions 🌱

Looking to the future, Dr. Shiri-Sverdlov is committed to advancing the understanding of liver diseases through cutting-edge research. Her work not only contributes to therapeutic advancements in NASH and hepatic inflammation but also inspires the next generation of scientists. Through her teaching roles, she continues to influence and guide students in Biomedical Sciences and Nutrition, instilling in them a commitment to rigorous research. Her legacy is further enriched by her leadership in scientific societies, where she champions innovative approaches to metabolic and hepatic health research.

🎓Publication 

Plasma cathepsin D as an early indicator of alcohol-related liver disease

  • Authors   :Li, M., Houben, T., Bitorina, A.V., … Thiele, M., Shiri-Sverdlov, R.
    JHEP Reports,
  • Year         :2024

The Modulatory Effects of Fatty Acids on Cancer Progression

  • Authors   :Westheim, A.J.F., Stoffels, L.M., Dubois, L.J., … Shiri-Sverdlov, R., Theys, J.
  • Journal    : Biomedicines
  • Year         :2023

All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma

  • Authors   :van Mourik, H., Li, M., Baumgartner, S., Theys, J., Shiri-Sverdlov, R.
  • Journal    :Biomedicines
  • Year         :2022

Fatty Acids as a Tool to Boost Cancer Immunotherapy Efficacy

  • Authors   : Westheim, A.J.F., Stoffels, L.M., Dubois, L.J., … Shiri-Sverdlov, R., Theys, J.
  • Journal    : Frontiers in Nutrition
  • Year         :2022

Serum CathepsinD in pregnancy: Relation with metabolic and inflammatory markers and effects of fish oils and probiotics

  • Authors   : Mokkala, K., Gustafsson, J., Vahlberg, T., … Plat, J., Laitinen, K.
  • Journal    :Nutrition, Metabolism and Cardiovascular Diseases
  • Year         :2022

Prof Dr. Elaine Leung|Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Prof Dr. Elaine Leung |Pharmacology|Best Researcher Award|

Prof Dr. Elaine Leung at Department of Biomedical Science, Faculty of Health Science, Macau

PROFILE  

scopus

 

Early Academic Pursuits 🎓

Elaine Lai-Han Leung embarked on her academic journey with a strong foundation in biological sciences, obtaining her BSc in Biology and Biochemistry from The Chinese University of Hong Kong in 2001. Her deep interest in biomedical sciences led her to pursue further studies, earning an MPhil in Biochemistry in 2003, followed by a PhD in Physiology in 2006 from the same institution. Her early academic pursuits laid the groundwork for a career marked by significant contributions to biomedical research, particularly in the fields of cancer biology and traditional Chinese medicine.

Professional Endeavors 🧬

Professor Leung’s professional career has been centered at the University of Macau, where she is a prominent figure in the Department of Biomedical Science, Faculty of Health Science. Over the years, she has established herself as a leading researcher, focusing on the intersection of modern biomedical sciences and traditional Chinese medicine. Her work has involved both academic research and collaborations with industry, where she has taken on numerous consultancy projects, contributing to the development of new therapies and drug discoveries.

Contributions and Research Focus 🔬

Professor Leung’s research is primarily focused on cancer biology, with an emphasis on non-small cell lung cancer (NSCLC). She has been the principal investigator (PI) or co-investigator (Co-I) on numerous research projects, many of which are aimed at understanding the mechanisms of drug resistance and the development of novel therapeutic strategies. Her ongoing research includes studies on KRAS resistance mechanisms, the role of gut microbiota in cancer immunomodulation, and the use of traditional Chinese medicine in treating various forms of cancer.

Some of her key projects include:

  • The relationship between KRAS resistance mechanisms and the immune microenvironment: An ongoing project at the University of Macau aimed at uncovering how KRAS mutations affect immune responses in cancer.
  • High-dimensional single-cell analysis of Sotorasib resistance clinical samples: This research seeks to identify new small molecule inhibitors for treating NSCLC.
  • Investigation of the anti-tumor effect of microbial valeric acid in NSCLC: Completed in 2023, this study explored how microbial byproducts can influence tumor immunity.

Accolades and Recognition 🏆

Professor Leung’s contributions to biomedical science have not gone unnoticed. She has been recognized with numerous awards and honors throughout her career, reflecting her standing in the scientific community. Her work has been cited extensively in leading scientific journals, with her citation index reflecting her influence in the fields of cancer biology and traditional Chinese medicine. Her collaboration with Nobel Laureate Erwin Neher on drug research further underscores her prominence in the field.

Impact and Influence 🌍

The impact of Professor Leung’s work extends beyond academia. Her research has significant implications for the development of new cancer therapies, particularly in the context of drug resistance. By bridging the gap between traditional Chinese medicine and modern biomedical research, she has opened new avenues for treatment that could benefit patients worldwide. Her work on gut microbiota and its role in cancer treatment, for instance, is pioneering in its approach and has the potential to revolutionize how cancer is treated.

Legacy and Future Contributions 🌟

As Professor Leung continues her work at the University of Macau, her legacy is already taking shape. She is helping to mentor the next generation of scientists while pushing the boundaries of what is possible in cancer research. Her ongoing projects, including those funded by significant grants, are expected to yield new insights into cancer biology and treatment. Looking ahead, her contributions will likely continue to influence the field of biomedical sciences, particularly in how traditional Chinese medicine is integrated into modern therapeutic strategies.

Research and Innovations 🧪

Completed/Ongoing Research Projects 📊

Professor Leung has completed numerous research projects, with many others ongoing. Her portfolio includes more than a dozen major projects, ranging from small-scale studies to large, collaborative efforts with industry partners. These projects have attracted significant funding, including:

  • Macao Science and Technology Development Fund (2021/2024): Investigating the combinational treatment effects of ginseng polysaccharides with immunotherapy in lung cancer, with a budget of USD 230,769.
  • Zhuhai UM Science and Technology Institute joint lab projects: Ongoing studies on drug resistance and immune microenvironment interactions in cancer, funded at approximately USD 641,000.

Citation Index 📚

Professor Leung’s work is highly regarded in the scientific community, as reflected by her citation index in databases such as Scopus and the Science Citation Index (SCI). Her research articles have been cited extensively, demonstrating the impact and relevance of her work in advancing biomedical science.

Consultancy/Industry Projects 🤝

Beyond academia, Professor Leung has engaged in several industry-sponsored projects, often serving as a consultant. These projects have allowed her to apply her research in practical settings, contributing to the development of new drugs and therapeutic strategies. Notably, she has collaborated with leading pharmaceutical companies like Janssen Pharmaceuticals, where her work on immunophenotyping in lung cancer patients has been highly influential.

Conclusion 🎯

Professor Elaine Lai-Han Leung’s career is a testament to the power of interdisciplinary research and collaboration. Her contributions to cancer biology, her innovative use of traditional Chinese medicine, and her commitment to bridging the gap between research and industry have made her a pivotal figure in her field. As she continues to explore new frontiers in biomedical science, her legacy will undoubtedly be one of lasting impact, shaping the future of cancer treatment and beyond.

🎓Publication 

Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer

  • Authors   :Zhang, Y.-Z., Lai, H.-L., Huang, C., … Wu, Q.-B., Leung, E.L.-H.
  • Journal    :Phytomedicine
  • Year         :2024

Genome engineering of the human gut microbiome

MMP14high macrophages orchestrate progressive pulmonary fibrosis in SR-Ag-induced hypersensitivity pneumonitis

  • Authors   :Peng, D., Li, J., Li, Y., … Yang, P., Li, G.
  • Journal    :Pharmacological Research.
  • Year         :2024

Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis